Drug Profile
SPN 811
Alternative Names: SPN-811Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Supernus Pharmaceuticals
- Class Behavioural disorder therapies
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- Available For Licensing Yes
Highest Development Phases
- No development reported Attention-deficit hyperactivity disorder
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Attention-deficit-hyperactivity-disorder in USA
- 23 Feb 2009 SPN 811 is available for licensing (http://www.supernus.com)
- 23 Feb 2009 Phase-I clinical trials in Attention-deficit hyperactivity disorder in USA (unspecified route)